Annals of Oncology Advance Access published online on October 3, 2006
Annals of Oncology, doi:10.1093/annonc/mdl315
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 The Albert Einstein Comprehensive Cancer Center, New York University, New York; Department of Molecular Genetics, New York University, New York
* To whom correspondence should be addressed. Background: We previously demonstrated that peak microtubule bundle formation (MBF) in peripheral blood mononuclear cells (PBMCs) occurs at the end of drug infusion and correlates with drug pharmacokinetics (PK). In the current study, a new expanded evaluation of drug target effect was undertaken. Patients and methods: Patients with advanced solid malignancies were treated with ixabepilone 40 mg/m2 administered as a 1-h i.v. infusion every 3 weeks. Blood, plasma, and tumor tissue sampling was carried out to characterize pharmacodynamics and PK. Results: Forty-seven patients were treated with 141 cycles of ixabepilone. In both PBMCs (n = 27) and tumor cells (n = 9), peak MBF occurred at the end of infusion; however, at 24-72 h after drug infusion, the number of cells with MBF was significantly greater in tumor cells, relative to PBMCs. A Hill model (EC50 = 109.65 ng/ml; r2 = 0.94) was fitted, which demonstrated a relationship between percentage of PBMCs with MBF and plasma ixabepilone concentration. The percentage of PBMCs with MBF at the end of infusion also correlated with severity of neutropenia (P = 0.050). Conclusions: Plasma ixabepilone concentration and severity of neutropenia correlate with the level of MBF in PBMCs. Therefore, this technically straightforward assay should be considered as a complement to the clinical development of novel microtubule-binding agents.
Received February 7, 2006
Revised July 12, 2006
Accepted July 24, 2006
original article
Peripheral blood mononuclear and tumor cell pharmacodynamics of the novel epothilone B analogue, ixabepilone
S. Mani 1 *, H. M. McDaid 2, A. Grossman 3, F. Muggia 4, S. Goel 5, T. Griffin 6, D. Colevas 7, S. B. Horwitz 2, and M. J. Egorin 8
2 The Albert Einstein Comprehensive Cancer Center, New York University, New York; Department of Molecular Pharmacology, Albert Einstein College of Medicine, New York University, New York
3 Department of Molecular Pharmacology, Albert Einstein College of Medicine, New York University, New York
4 Comprehensive Cancer Center of NYU School of Medicine, New York University, New York
5 The Albert Einstein Comprehensive Cancer Center, New York University, New York
6 Bristol-Myers Squibb, Wallingford
7 Cancer Therapy Evaluation Program of the National Cancer Institute, Bethesda
8 University of Pittsburgh Cancer Institute, Pittsburgh, USA
S. Mani, E-mail: smani{at}montefiore.org
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  L. Boehnke Michaud The optimal therapeutic use of ixabepilone in patients with locally advanced or metastatic breast cancer Journal of Oncology Pharmacy Practice, June 1, 2009; 15(2): 95 - 106. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Goel, M. Cohen, S. N. Comezoglu, L. Perrin, F. Andre, D. Jayabalan, L. Iacono, A. Comprelli, V. T. Ly, D. Zhang, et al. The Effect of Ketoconazole on the Pharmacokinetics and Pharmacodynamics of Ixabepilone: A First in Class Epothilone B Analogue in Late-Phase Clinical Development Clin. Cancer Res., May 1, 2008; 14(9): 2701 - 2709. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Lee and S. M. Swain The Epothilones: Translating from the Laboratory to the Clinic Clin. Cancer Res., March 15, 2008; 14(6): 1618 - 1624. [Abstract] [Full Text] [PDF]
|
|